Flavonoid diversity and roles in the lipopolysaccharide-mediated inflammatory response of monocytes and macrophages

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mihlan M, Safaiyan S, Stecher M, Paterson N, Lämmermann T. Surprises from intravital imaging of the innate immune response. Ann. Rev. Cell Dev. Biol. 38(1), 467–489 (2022).
  Medline CASGoogle Scholar
• 2. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27(1), 669–692 (2009).
  Medline CASGoogle Scholar
• 3. Ardura JA, Rackov G, Izquierdo E, Alonso V, Gortazar AR, Escribese MM. Targeting macrophages: friends or foes in disease? Front. Pharmacol. 10(1255), (2019).
  MedlineGoogle Scholar
• 4. Chen L, Deng H, Cui H et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9(6), 7204–7218 (2017).
  MedlineGoogle Scholar
• 5. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11(11), 762–774 (2011). • Review describing the mechanisms that control monocyte trafficking under infectious and inflammatory conditions.
  Medline CASGoogle Scholar
• 6. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 16(3), 379–414 (2003).
  Medline CASGoogle Scholar
• 7. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71(1), 635–700 (2002).
  Medline CASGoogle Scholar
• 8. Alvim J, Severino RP, Marques EF et al. Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors. J. Comb. Chem. 12(5), 687–695 (2010).
  Medline CASGoogle Scholar
• 9. Hert J, Irwin JJ, Laggner C, Keiser MJ, Shoichet BK. Quantifying biogenic bias in screening libraries. Nat. Chem. Biol. 5(7), 479–483 (2009).
  Medline CASGoogle Scholar
• 10. Tapas AR, Sakarkar D, Kakde R. Flavonoids as nutraceuticals: a review. Trop. J. Pharm. Res. 7(3), 1089–1099 (2008).
  Google Scholar
• 11. Hughes SD, Ketheesan N, Haleagrahara N. The therapeutic potential of plant flavonoids on rheumatoid arthritis. Crit. Rev. Food Sci. Nutr. 57(17), 3601–3613 (2017).
  Medline CASGoogle Scholar
• 12. Vezza T, Rodríguez-Nogales A, Algieri F, Utrilla MP, Rodriguez-Cabezas ME, Galvez J. Flavonoids in inflammatory bowel disease: a review. Nutrients 8(4), 211 (2016).
  MedlineGoogle Scholar
• 13. Rakha A, Umar N, Rabail R et al. Anti-inflammatory and anti-allergic potential of dietary flavonoids: a review. Biomed. Pharmacother. 156, 113945 (2022).
  Medline CASGoogle Scholar
• 14. Filingeri V, Buonomo O, Sforza D. Use of flavonoids for the treatment of symptoms after hemorrhoidectomy with radiofrequency scalpel. Eur. Rev. Med. Pharmacol. Sci. 18(5), 612–616 (2014).
  Medline CASGoogle Scholar
• 15. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, Martínez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 58(9), 537–552 (2009).
  Medline CASGoogle Scholar
• 16. Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chem. 299, 125124 (2019).
  Medline CASGoogle Scholar
• 17. Rathee P, Chaudhary H, Rathee S, Rathee D, Kumar V, Kohli K. Mechanism of action of flavonoids as anti-inflammatory agents: a review. Inflamm. Allergy Drug Targets 8(3), 229–235 (2009).
  Medline CASGoogle Scholar
• 18. Manthey JA. Biological properties of flavonoids pertaining to inflammation. Microcirculation 7(Suppl. 1), S29–S34 (2000).
  Medline CASGoogle Scholar
• 19. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J. Pharmacol. Sci. 96(3), 229–245 (2004).
  Medline CASGoogle Scholar
• 20. Mahapatra DK, Bharti SK, Asati V. Chalcone derivatives: anti-inflammatory potential and molecular targets perspectives. Curr. Top. Med. Chem. 17(28), 3146–3169 (2017).
  Medline CASGoogle Scholar
• 21. Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front. Physiol. 8, doi: 10.3389/fphys.2017.00508 (2017).
  Google Scholar
• 22. Park BS, Lee J-O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 45, e66 (2013).
  MedlineGoogle Scholar
• 23. Zhang Y, Liang X, Bao X, Xiao W, Chen G. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur. J. Med. Chem. 235, 114291 (2022).
  Medline CASGoogle Scholar
• 24. Pålsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology 113(2), 153–162 (2004).
  Medline CASGoogle Scholar
• 25. Madalina M, Deleanu M, Manduteanu I et al. Lipopolysaccharide-induced inflammation in monocytes/macrophages is blocked by liposomal delivery of Gi-protein inhibitor. Int. J. Nanomedicine 13, 63–76 (2018).
  Google Scholar
• 26. Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J. Exp. Med. 185(9), 1661–1670 (1997).
  Medline CASGoogle Scholar
• 27. Zhang X, Wang G, Gurley EC, Zhou H. Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PLOS ONE 9(9), e107072 (2014).
  MedlineGoogle Scholar
• 28. Rossol M, Heine H, Meusch U et al. LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol. 31(5), 379–446 (2011).
  Medline CASGoogle Scholar
• 29. Nunes-Alves C. Host response: new LPS receptors discovered. Nat. Rev. Microbiol. 12(10), 658–658 (2014).
  Medline CASGoogle Scholar
• 30. Shi J, Zhao Y, Wang Y et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514(7521), 187–192 (2014). • Review describing the mechanism underlying cytosolic lipopolysaccharide sensing and the responsible pattern recognition receptor in human monocytes.
  Medline CASGoogle Scholar
• 31. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783–801 (2006).
  Medline CASGoogle Scholar
• 32. Valkov E, Stamp A, Dimaio F et al. Crystal structure of toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc. Natl Acad. Sci. USA 108(36), 14879–14884 (2011).
  Medline CASGoogle Scholar
• 33. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 13(2), 85–94 (2001).
  Medline CASGoogle Scholar
• 34. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15(2), 87–103 (2015).
  Medline CASGoogle Scholar
• 35. May MJ, Ghosh S. IκB kinases: kinsmen with different crafts. Science 284(5412), 271–273 (1999).
  Medline CASGoogle Scholar
• 36. Nakano H, Shindo M, Sakon S et al. Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl Acad. Sci. USA 95(7), 3537–3542 (1998).
  Medline CASGoogle Scholar
• 37. Irie T, Muta T, Takeshige K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-κB in lipopolysaccharide-stimulated macrophages. FEBS Lett. 467(2–3), 160–164 (2000).
  Medline CASGoogle Scholar
• 38. Kopp E, Medzhitov R, Carothers J et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev. 13(16), 2059–2071 (1999).
  Medline CASGoogle Scholar
• 39. Takaesu G, Kishida S, Hiyama A et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by Linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5(4), 649–658 (2000).
  Medline CASGoogle Scholar
• 40. Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat. Rev. Immunol. 8(11), 837–848 (2008).
  Medline CASGoogle Scholar
• 41. Kang Y-J, Wingerd BA, Arakawa T, Smith WL. Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J. Immunol. 177(11), 8111–8122 (2006).
  Medline CASGoogle Scholar
• 42. Díaz-Muñoz MD, Osma-García IC, Cacheiro-Llaguno C, Fresno M, Íñiguez MA. Coordinated up-regulation of cyclooxygenase-2 and microsomal prostaglandin E synthase 1 transcription by nuclear factor kappa B and early growth response-1 in macrophages. Cell Signal. 22(10), 1427–1436 (2010).
  Medline CASGoogle Scholar
• 43. Griscavage JM, Wilk S, Ignarro LJ. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc. Natl Acad. Sci. USA 93(8), 3308–3312 (1996).
  Medline CASGoogle Scholar
• 44. Lowenstein CJ, Alley EW, Raval P et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc. Natl Acad. Sci. USA 90(20), 9730–9734 (1993).
  Medline CASGoogle Scholar
• 45. Stefanová I, Corcoran ML, Horak EM, Wahl LM, Bolen JB, Horak ID. Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn. J. Biol. Chem. 268(28), 20725–20728 (1993).
  Medline CASGoogle Scholar
• 46. Seow V, Lim J, Iyer A et al. Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J. Immunol. 191(8), 4308–4316 (2013).
  Medline CASGoogle Scholar
• 47. Rao KM. MAP kinase activation in macrophages. J. Leukoc. Biol. 69(1), 3–10 (2001).
  Medline CASGoogle Scholar
• 48. Herrera-Velit P, Knutson KL, Reiner NE. Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-ζ in bacterial lipopolysaccharide-treated human monocytes. J. Biol. Chem. 272(26), 16445–16452 (1997).
  Medline CASGoogle Scholar
• 49. Loegering DJ, Lennartz MR. Protein kinase C and toll-like receptor signaling. Enzyme Res. 2011, 7 (2011).
  Google Scholar
• 50. Díaz-Guerra MJ, Castrillo A, Martín-Sanz P, Boscá L. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J. Immunol. 162(10), 6184–6190 (1999).
  Medline CASGoogle Scholar
• 51. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277(35), 32124–32132 (2002).
  Medline CASGoogle Scholar
• 52. Lee JS, Nauseef WM, Moeenrezakhanlou A et al. Monocyte p110α phosphatidylinositol 3-kinase regulates phagocytosis, the phagocyte oxidase, and cytokine production. J. Leukoc. Biol. 81(6), 1548–1561 (2007).
  Medline CASGoogle Scholar
• 53. Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N. Genetic analysis of the role of the PI3K–Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 180(6), 4218–4226 (2008).
  Medline CASGoogle Scholar
• 54. Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15(10), 599–614 (2015).
  Medline CASGoogle Scholar
• 55. Diaz-Meco MT, Dominguez I, Sanz L et al. Zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro. EMBO J. 13(12), 2842–2848 (1994).
  Medline CASGoogle Scholar
• 56. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6(8), 777–784 (2005).
  Medline CASGoogle Scholar
• 57. Cortés-Vieyra R, Bravo-Patiño A, Valdez-Alarcón JJ, Juárez MC, Finlay BB, Baizabal-Aguirre VM. Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. J. Inflamm. (Lond.) 9(1), 1–9 (2012).
  MedlineGoogle Scholar
• 58. Medunjanin S, Schleithoff L, Fiegehenn C, Weinert S, Zuschratter W, Braun-Dullaeus RC. GSK-3β controls NF-kappaB activity via IKKγ/NEMO. Sci. Rep. 6(1), 38553 (2016).
  Medline CASGoogle Scholar
• 59. Miyake K. Invited review: roles for accessory molecules in microbial recognition by toll-like receptors. J. Endotoxin Res. 12(4), 195–204 (2006).
  Medline CASGoogle Scholar
• 60. Kim HM, Park BS, Kim J-I et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 130(5), 906–917 (2007).
  Medline CASGoogle Scholar
• 61. Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191–1195 (2009).
  Medline CASGoogle Scholar
• 62. Park SH, Kim ND, Jung J-K, Lee C-K, Han S-B, Kim Y. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Pharmacol. Ther. 133(3), 291–298 (2012).
  Medline CASGoogle Scholar
• 63. Gradišar H, Keber MM, Pristovšek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J. Leukoc. Biol. 82(4), 968–974 (2007).
  Medline CASGoogle Scholar
• 64. Peluso MR, Miranda CL, Hobbs DJ, Proteau RR, Stevens JF. Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-Activated THP-1 monocytes: structure–activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2). Planta Med. 76(14), 1536–1543 (2010).
  Medline CASGoogle Scholar
• 65. Roh E, Lee H-S, Kwak J-A et al. MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. J. Infect. Dis. 203(7), 1012–1020 (2011).
  Medline CASGoogle Scholar
• 66. Kim SY, Koo JE, Seo YJ et al. Suppression of toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br. J. Pharmacol. 168(8), 1933–1945 (2013).
  Medline CASGoogle Scholar
• 67. Chen G, Zhang Y, Liu X et al. Discovery of a new inhibitor of myeloid differentiation 2 from cinnamamide derivatives with anti-inflammatory activity in sepsis and acute lung injury. J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01574 (.2016) (Online).
  Google Scholar
• 68. Wang Y, Shan X, Chen G et al. MD-2 as the target of a novel small molecule, L6H 21, in the attenuation of LPS-induced inflammatory response and sepsis. Br. J. Pharmacol. 172(17), 4391–4405 (2015). • Presents a flavonoid derivative as a sepsis treatment and emphasizes MD-2 as a key target for inflammatory disorders.
  Medline CASGoogle Scholar
• 69. Zhang Y, Wu J, Ying S et al. Discovery of new MD2 inhibitor from chalcone derivatives with anti-inflammatory effects in LPS-induced acute lung injury. Sci. Rep. 6(1), 25130 (2016).
  Medline CASGoogle Scholar
• 70. Ye J, Guan M, Lu Y et al. Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2. Eur. J. Pharmacol. 852, 151–158 (2019).
  Medline CASGoogle Scholar
• 71. Yang Y, Han C, Sheng Y et al. The mechanism of aureusidin in suppressing inflammatory response in acute liver injury by regulating MD2. Front. Pharmacol. 11, 570776 (2020).
  Medline CASGoogle Scholar
• 72. Yue B, Ren J, Yu Z et al. Pinocembrin alleviates ulcerative colitis in mice via regulating gut microbiota, suppressing TLR4/MD2/NF-κB pathway and promoting intestinal barrier. Biosci. Rep. 40(7), BSR20200986 (2020).
  Medline CASGoogle Scholar
• 73. Wu P, Yan H, Qi J et al. L6H9 attenuates LPS-induced acute lung injury in rats through targeting MD2. Drug Dev. Res. 81(1), 85–92 (2020).
  Medline CASGoogle Scholar
• 74. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 84(6), 853–862 (1996).
  Medline CASGoogle Scholar
• 75. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388(6642), 548–554 (1997).
  Medline CASGoogle Scholar
• 76. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem. Sci. 29(2), 72–79 (2004).
  Medline CASGoogle Scholar
• 77. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18(1), 621–663 (2000).
  Medline CASGoogle Scholar
• 78. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434(7037), 1138–1143 (2005).
  Medline CASGoogle Scholar
• 79. O'Connell MA, Bennett BL, Mercurio F, Manning AM, Mackman N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J. Biol. Chem. 273(46), 30410–30414 (1998).
  MedlineGoogle Scholar
• 80. Hu Y, Baud V, Delhase M et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 284(5412), 316–320 (1999).
  Medline CASGoogle Scholar
• 81. Liddle J, Bamborough P, Barker MD et al. 4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy. Bioorg. Med. Chem. Lett. 22(16), 5222–5226 (2012).
  Medline CASGoogle Scholar
• 82. Christopher JA, Bamborough P, Alder C et al. Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IκB kinase-β (IKK-β). J. Med. Chem. 52(9), 3098–3102 (2009).
  Medline CASGoogle Scholar
• 83. Crombie AL, Sum F-W, Powell DW et al. Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKβ inhibitors. Bioorg. Med. Chem. Lett. 20(12), 3821–3825 (2010).
  Medline CASGoogle Scholar
• 84. Park H, Shin Y, Choe H, Hong S. Computational design and discovery of nanomolar inhibitors of IκB kinase β. J. Am. Chem. Soc. 137(1), 337–348 (2015).
  Medline CASGoogle Scholar
• 85. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-κB and NF-κB-regulated gene expression through direct inhibition of IκBα kinase β on cysteine 179 residue. J. Biol. Chem. 282(24), 17340–17350 (2007).
  Medline CASGoogle Scholar
• 86. Byun M-S, Choi J, Jue D-M. Cysteine-179 of IκB kinase β plays a critical role in enzyme activation by promoting phosphorylation of activation loop serines. Exp. Mol. Med. 38, 546–552 (2006).
  Medline CASGoogle Scholar
• 87. Harikumar KB, Kunnumakkara AB, Ahn KS et al. Modification of the cysteine residues in IκBα kinase and NF-κB (p65) by xanthohumol leads to suppression of NF-κB–regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113(9), 2003–2013 (2009).
  Medline CASGoogle Scholar
• 88. Funakoshi-Tago M, Tanabe S, Tago K et al. Licochalcone a potently inhibits tumor necrosis factor α-induced nuclear factor-κB activation through the direct inhibition of IκB kinase complex activation. Mol. Pharmacol. 76(4), 745–753 (2009).
  Medline CASGoogle Scholar
• 89. Funakoshi-Tago M, Ohsawa K, Ishikawa T et al. Inhibitory effects of flavonoids extracted from Nepalese propolis on the LPS signaling pathway. Int. Immunopharmacol. 40, 550–560 (2016).
  Medline CASGoogle Scholar
• 90. Kim J-Y, Park SJ, Yun K-J, Cho Y-W, Park H-J, Lee K-T. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-κB in RAW 264.7 macrophages. Eur. J. Pharmacol. 584(1), 175–184 (2008).
  Medline CASGoogle Scholar
• 91. Kim Y-J, Kim H-C, Ko H, Amor EC, Lee JW, Yang HO. Inhibitory effects of aurentiacin from Syzygium samarangense on lipopolysaccharide-induced inflammatory response in mouse macrophages. Food Chem. Toxicol. 50(3–4), 1027–1035 (2012).
  Medline CASGoogle Scholar
• 92. Li C, Yang D, Cao X et al. LFG-500, a newly synthesized flavonoid, attenuates lipopolysaccharide-induced acute lung injury and inflammation in mice. Biochem. Pharmacol. 113, 57–69 (2016).
  Medline CASGoogle Scholar
• 93. Sun Y-W, Bao Y, Yu H et al. Anti-rheumatoid arthritis effects of flavonoids from Daphne genkwa. Int. Immunopharmacol. 83, 106384 (2020).
  Medline CASGoogle Scholar
• 94. Dhar R, Kimseng R, Chokchaisiri R et al. 2′, 4-Dihydroxy-3′, 4′, 6′-trimethoxychalcone from Chromolaena odorata possesses anti-inflammatory effects via inhibition of NF-κB and p38 MAPK in lipopolysaccharide-activated RAW 264.7 macrophages. Immunopharmacol. Immunotoxicol. 40(1), 43–51 (2018).
  Medline CASGoogle Scholar
• 95. Elsasser S, Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat. Cell Biol. 7(8), 742–749 (2005).
  Medline CASGoogle Scholar
• 96. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-κB regulatory pathways. Annu. Rev. Biochem. 78(1), 769–796 (2009).
  Medline CASGoogle Scholar
• 97. Musial A, Eissa NT. Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J. Biol. Chem. 276(26), 24268–24273 (2001).
  Medline CASGoogle Scholar
• 98. Mbonye UR, Wada M, Rieke CJ, Tang H-Y, Dewitt DL, Smith WL. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J. Biol. Chem. 281(47), 35770–35778 (2006).
  Medline CASGoogle Scholar
• 99. Silswal N, Reis J, Qureshi AA, Papasian C, Qureshi N. Of mice and men: proteasome's role in LPS-induced inflammation and tolerance. Shock 47(4), 445–454 (2017).
  Medline CASGoogle Scholar
• 100. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade™ (bortezomib). Cancer Invest. 22(2), 304–311 (2004).
  Medline CASGoogle Scholar
• 101. McBride A, Klaus JO, Stockerl-Goldstein K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am. J. Health Syst. Pharm. 72(5), 353–360 (2015).
  Medline CASGoogle Scholar
• 102. Beck F, Unverdorben P, Bohn S et al. Near-atomic resolution structural model of the yeast 26S proteasome. Proc. Natl Acad. Sci. USA 109(37), 14870–14875 (2012).
  Medline CASGoogle Scholar
• 103. Śledź P, Baumeister W. Structure-driven developments of 26S proteasome inhibitors. Annu. Rev. Pharmacol. Toxicol. 56(1), 191–209 (2016).
  Medline CASGoogle Scholar
• 104. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol. 70(1), 426–433 (2006).
  Medline CASGoogle Scholar
• 105. Shi D, Jiang P. A different facet of p53 function: regulation of immunity and inflammation during tumor development. Front. Cell Dev. Biol. 9, 762651 (2021).
  MedlineGoogle Scholar
• 106. Bazzaro M, Anchoori RK, Mudiam MKR et al. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J. Med. Chem. 54(2), 449–456 (2011).
  Medline CASGoogle Scholar
• 107. Lee Y-H, Yun J, Jung J-C, Seikwan O, Jung Y-S. Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells. Pharmazie 71(5), 274–279 (2016).
  Medline CASGoogle Scholar
• 108. Wang J, Wang Y, He S, Wang Z, Deng Q, Liang H. Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction. J. Biochem. Mol. Toxicol. 35(11), e22894 (2021).
  Medline CASGoogle Scholar
• 109. Qureshi N, Perera P-Y, Shen J et al. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J. Immunol. 171(3), 1515–1525 (2003).
  Medline CASGoogle Scholar
• 110. Ren B-Z, Ablise M, Yang X-C, Liao B-E, Yang Z. Synthesis and biological evaluation of α-methyl-chalcone for anti-cervical cancer activity. Med. Chem. Res. 26(9), 1871–1883 (2017).
  CASGoogle Scholar
• 111. Chang T-L. Inhibitory effect of flavonoids on 26S proteasome activity. J. Agric. Food Chem. 57(20), 9706–9715 (2009).
  Medline CASGoogle Scholar
• 112. Pradhan D, Pradhan RK, Tripathy G, Pradhan S. Inhibition of proteasome activity by the dietary flavonoid quercetin associated with growth inhibition in cultured breast cancer cells and xenografts. J. Young Pharm. 7(3), 225 (2015).
  CASGoogle Scholar
• 113. Ding Y, Chen X, Wang B, Yu B, Ge J, Shi X. Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells. Can. J. Physiol. Pharmacol. 96(5), 521–526 (2018).
  Medline CASGoogle Scholar
• 114. Chang T-L, Wang C-H. Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention. Biol. Chem. 394(4), 561–575 (2013).
  Medline CASGoogle Scholar
• 115. Singh V, Sharma V, Verma V et al. Apigenin manipulates the ubiquitin–proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. Eur. J. Nutr. 54(8), 1255–1267 (2015).
  Medline CASGoogle Scholar
• 116. Li S, Yang L-J, Wang P et al. Dietary apigenin potentiates the inhibitory effect of interferon-α on cancer cell viability through inhibition of 26S proteasome-mediated interferon receptor degradation. Food Nutr. Res. 60(1), 31288 (2016).
  MedlineGoogle Scholar
• 117. Shim SH. 20S proteasome inhibitory activity of flavonoids isolated from Spatholobus suberectus. Phytother. Res. 25(4), 615–618 (2011).
  Medline CASGoogle Scholar
• 118. Piedfer M, Bouchet S, Tang R, Billard C, Dauzonne D, Bauvois B. p70S6 kinase is a target of the novel proteasome inhibitor 3, 3′-diamino-4′-methoxyflavone during apoptosis in human myeloid tumor cells. Biochim. Biophys. Acta Molecular Cell Research 1833(6), 1316–1328 (2013).
  CASGoogle Scholar
• 119. Pevzner Y, Metcalf R, Kantor M, Sagaro D, Daniel K. Recent advances in proteasome inhibitor discovery. Expert Opin. Drug Discov. 8(5), 537–568 (2013).
  Medline CASGoogle Scholar
• 120. Metcalf R, Scott LM, Daniel KG, Dou QP. Proteasome inhibitor patents (2010 – present). Expert. Opin. Ther. Pat. 24(4), 369–382 (2014).
  Medline CASGoogle Scholar
• 121. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology 47(4), 409–414 (2008).
  Medline CASGoogle Scholar
• 122. Champion A, Picaud A, Henry Y. Reassessing the MAP3K and MAP4K relationships. Trends Plant Sci. 9(3), 123–129 (2004).
  Medline CASGoogle Scholar
• 123. Moens U, Kostenko S, Sveinbjørnsson B. The role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes 4(2), 101 (2013).
  MedlineGoogle Scholar
• 124. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta Molecular Cell Research 1813(9), 1619–1633 (2011).
  CASGoogle Scholar
• 125. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12(1), 9–18 (2002).
  Medline CASGoogle Scholar
• 126. Hoshino R, Chatani Y, Yamori T et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18(3), 813–822 (1999).
  Medline CASGoogle Scholar
• 127. Zheng CF, Guan KL. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem. 268(15), 11435–11439 (1993).
  Medline CASGoogle Scholar
• 128. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92(17), 7686–7689 (1995).
  Medline CASGoogle Scholar
• 129. Redwan IN, Dyrager C, Solano C et al. Towards the development of chromone-based MEK1/2 modulators. Eur. J. Med. Chem. 85, 127–138 (2014).
  Medline CASGoogle Scholar
• 130. Xagorari A, Roussos C, Papapetropoulos A. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br. J. Pharmacol. 136(7), 1058–1064 (2002).
  Medline CASGoogle Scholar
• 131. Lee J-P, Li Y-C, Chen H-Y et al. Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils. Acta Pharmacol. Sin. 31(7), 831–838 (2010).
  Medline CASGoogle Scholar
• 132. Hambleton J, Weinstein SL, Lem L, Defranco AL. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc. Natl Acad. Sci. USA 93(7), 2774–2778 (1996).
  Medline CASGoogle Scholar
• 133. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development. Curr. Opin. Cell Biol. 10(2), 205–219 (1998).
  Medline CASGoogle Scholar
• 134. Lee E, Jeong K-W, Shin A et al. Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway. BMB Rep. 46(12), 594–599 (2013).
  Medline CASGoogle Scholar
• 135. Lee E, Jeong K-W, Jnawali H, Shin A, Heo Y-S, Kim Y. Cytotoxic activity of 3,6-dihydroxyflavone in human cervical cancer cells and its therapeutic effect on c-Jun N-terminal kinase inhibition. Molecules 19(9), 13200 (2014).
  MedlineGoogle Scholar
• 136. Jnawali HN, Jeon D, Park Y-G, Lee E, Heo Y-S, Kim Y. Rhamnetin is a potent inhibitor of extracellular signal-regulated kinase 1 and c-Jun N-terminal kinase 1. Bull. Korean Chem. Soc. 36(8), 2107–2110 (2015).
  CASGoogle Scholar
• 137. Baek S, Kang NJ, Popowicz GM et al. Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. J. Mol. Biol. 425(2), 411–423 (2013).
  Medline CASGoogle Scholar
• 138. Hierold J, Baek S, Rieger R et al. Design, synthesis, and biological evaluation of quercetagetin analogues as JNK1 inhibitors. Chemistry 21(47), 16887–16894 (2015).
  Medline CASGoogle Scholar
• 139. Gao Y, Liu F, Fang L, Cai R, Zong C, Qi Y. Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101/MKP-1/MAPK pathway in LPS-activated macrophages. PLOS ONE 9(5), e96741 (2014).
  MedlineGoogle Scholar
• 140. Kim K-Y, Kang H. Sakuranetin inhibits inflammatory enzyme, cytokine, and costimulatory molecule expression in macrophages through modulation of JNK, p38, and STAT1. Evid. Based Complement. Alternat. Med. 2016, (2016).
  Google Scholar
• 141. Cho YH, Kim NH, Khan I et al. Anti-inflammatory potential of quercetin-3-O-β-D-(‘2’-galloyl)-glucopyranoside and quercetin isolated from Diospyros kaki calyx via suppression of MAP signaling molecules in LPS-induced RAW 264.7 macrophages. J. Food Sci. 81(10), C2447–C2456 (2016).
  Medline CASGoogle Scholar
• 142. Park J-Y, Lim M-S, Kim S-I et al. Quercetin-3-O-β-D-glucuronide suppresses lipopolysaccharide-induced JNK and ERK phosphorylation in LPS-challenged RAW264.7 cells. Biomol. Ther. (Seoul) 24(6), 610 (2016).
  Medline CASGoogle Scholar
• 143. Lee HN, Shin SA, Choo GS et al. Anti-inflammatory effect of quercetin and galangin in LPS-stimulated RAW264.7 macrophages and DNCB-induced atopic dermatitis animal models. Int. J. Mol. Med. 41(2), 888–898 (2018).
  Medline CASGoogle Scholar
• 144. Xin Y-J, Choi S, Roh K-B et al. Anti-inflammatory activity and mechanism of isookanin, isolated by bioassay-guided fractionation from Bidens pilosa L. Molecules 26(2), 255 (2021).
  Medline CASGoogle Scholar
• 145. Park MY, Ha SE, Kim HH et al. Scutellarein inhibits LPS-induced inflammation through NF-κB/MAPKs signaling pathway in RAW264.7 cells. Molecules 27(12), 3782 (2022).
  Medline CASGoogle Scholar
• 146. Hada Y, Uchida HA, Wada J. Fisetin attenuates lipopolysaccharide-induced inflammatory responses in macrophage. Biomed. Res. Int. 2021, 5570885 (2021).
  MedlineGoogle Scholar
• 147. Kim S-C, Kang S-H, Jeong S-J, Kim S-H, Ko HS, Kim S-H. Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells. Immunopharmacol. Immunotoxicol. 34(4), 645–650 (2012).
  Medline CASGoogle Scholar
• 148. Kim EJ, Lee MY, Jeon YJ. Silymarin inhibits morphological changes in LPS-stimulated macrophages by blocking NF-κB pathway. Korean J. Physiol. Pharmacol. 19(3), 211–218 (2015).
  Medline CASGoogle Scholar
• 149. Lee D-H, Park J-K, Choi J, Jang H, Seol J-W. Anti-inflammatory effects of natural flavonoid diosmetin in IL-4 and LPS-induced macrophage activation and atopic dermatitis model. Int. Immunopharmacol. 89, 107046 (2020).
  Medline CASGoogle Scholar
• 150. Xie C, Kang J, Li Z et al. The açaí flavonoid velutin is a potent anti-inflammatory agent: blockade of LPS-mediated TNF-α and IL-6 production through inhibiting NF-κB activation and MAPK pathway. J. Nutr. Biochem. 23(9), 1184–1191 (2012).
  Medline CASGoogle Scholar
• 151. Abarikwu SO. Kolaviron, a natural flavonoid from the seeds of Garcinia kola, reduces LPS-induced inflammation in macrophages by combined inhibition of IL-6 secretion, and inflammatory transcription factors, ERK1/2, NF-κB, p38, Akt, pc-JUN and JNK. Biochim. Biophys. Acta General Subjects 1840(7), 2373–2381 (2014).
  CASGoogle Scholar
• 152. Chung YC, Lee A, Ryuk JA, Hwang Y-H. Isodorsmanin a prevents inflammatory response in LPS-stimulated macrophages by inhibiting the JNK and NF-κB signaling pathways. Curr. Issues Mol. Biol. 45(2), 1601–1612 (2023).
  Medline CASGoogle Scholar
• 153. Jin XY, Lee SH, Park PH et al. 2′-Methoxy-4′ 6′-bis (methoxymethoxy) chalcone inhibits nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 macrophages. Basic Clin. Pharmacol. Toxicol. 106(6), 454–460 (2010).
  Medline CASGoogle Scholar
• 154. Reddy MVB, Hung H-Y, Kuo P-C et al. Synthesis and biological evaluation of chalcone, dihydrochalcone, and 1, 3-diarylpropane analogs as anti-inflammatory agents. Bioorg. Med. Chem. Lett. 27(7), 1547–1550 (2017).
  MedlineGoogle Scholar
• 155. Jin X, Song S, Wang J, Zhang Q, Qiu F, Zhao F. Tiliroside, the major component of Agrimonia pilosa Ledeb ethanol extract, inhibits MAPK/JNK/p38-mediated inflammation in lipopolysaccharide-activated RAW 264.7 macrophages. Exp. Ther. Med. 12(1), 499–505 (2016).
  Medline CASGoogle Scholar
• 156. Lee E, Jeong K-W, Shin A, Kim Y. Anti-inflammatory activity of 3, 6, 3′-trihydroxyflavone in mouse macrophages, in vitro. Bull. Korean Chem. Soc. 35(11), 3169–3174 (2014).
  CASGoogle Scholar
• 157. Jnawali HN, Lee E, Jeong K-W, Shin A, Heo Y-S, Kim Y. Anti-inflammatory activity of rhamnetin and a model of its binding to c-Jun NH2-terminal kinase 1 and p38 MAPK. J. Nat. Prod. 77(2), 258–263 (2014).
  Medline CASGoogle Scholar
• 158. Han J, Lee J, Bibbs L, Ulevitch R. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265(5173), 808–811 (1994).
  Medline CASGoogle Scholar
• 159. Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13(9), 679–692 (2013).
  Medline CASGoogle Scholar
• 160. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 273(21), 12901–12908 (1998).
  Medline CASGoogle Scholar
• 161. Masuko-Hongo K, Berenbaum F, Humbert L, Salvat C, Goldring MB, Thirion S. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheumatol. 50(9), 2829–2838 (2004).
  CASGoogle Scholar
• 162. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta Molecular Cell Research 1773(8), 1358–1375 (2007).
  CASGoogle Scholar
• 163. Feng G-J, Goodridge HS, Harnett MM et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J. Immunol. 163(12), 6403–6412 (1999).
  Medline CASGoogle Scholar
• 164. Pietersma A, Tilly BC, Gaestel M et al. P38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem. Biophys. Res. Commun. 230(1), 44–48 (1997).
  Medline CASGoogle Scholar
• 165. Tong L, Pav S, White DM et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Mol. Biol. 4(4), 311–316 (1997).
  CASGoogle Scholar
• 166. Borst O, Walker B, Münzer P et al. Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation. Cell. Physiol. Biochem. 31(6), 914–924 (2013).
  Medline CASGoogle Scholar
• 167. Guenthoer P, Fuchs K, Reischl G et al. Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis. Inflammopharmacology 27(6), 1217–1227 (2019).
  Medline CASGoogle Scholar
• 168. Koeberle SC, Romir J, Fischer S et al. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat. Chem. Biol. 8(2), 141–143 (2012).
  CASGoogle Scholar
• 169. Dyrager C, Möllers LN, Kjäll LK et al. Design, synthesis, and biological evaluation of chromone-based p38 MAP kinase inhibitors. J. Med. Chem. 54(20), 7427–7431 (2011).
  Medline CASGoogle Scholar
• 170. Hassan AH, Yoo SY, Lee KW et al. Repurposing mosloflavone/5, 6, 7-trimethoxyflavone-resveratrol hybrids: discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. Eur. J. Med. Chem. 180, 253–267 (2019).
  Medline CASGoogle Scholar
• 171. Youn CK, Park SJ, Lee MY et al. Silibinin inhibits LPS-induced macrophage activation by blocking p38 MAPK in RAW 264.7 cells. Biomol. Ther. (Seoul) 21(4), 258 (2013).
  Medline CASGoogle Scholar
• 172. Liu X, Wang N, Fan S et al. The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway. Sci. Rep. 6(1), 1–14 (2016).
  MedlineGoogle Scholar
• 173. Chen Y, Lin Y, Li Y, Li C. Total flavonoids of Hedyotis diffusa Willd inhibit inflammatory responses in LPS-activated macrophages via suppression of the NF-κB and MAPK signaling pathways. Exp. Ther. Med. 11(3), 1116–1122 (2016).
  Medline CASGoogle Scholar
• 174. Jia X, Zhang C, Bao J et al. Flavonoids from Rhynchosia minima root exerts anti-inflammatory activity in lipopolysaccharide-stimulated RAW 264.7 cells via MAPK/NF-κB signaling pathway. Inflammopharmacology 28(1), 289–297 (2020).
  Medline CASGoogle Scholar
• 175. Jiang F, Guan H, Liu D, Wu X, Fan M, Han J. Flavonoids from sea buckthorn inhibit the lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages through the MAPK and NF-κB pathways. Food and Function 8(3), 1313–1322 (2017).
  Medline CASGoogle Scholar
• 176. Kang SR, Park KI, Park HS et al. Anti-inflammatory effect of flavonoids isolated from Korea Citrus aurantium L. on lipopolysaccharide-induced mouse macrophage RAW 264.7 cells by blocking of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signalling pathways. Food Chem. 129(4), 1721–1728 (2011).
  CASGoogle Scholar
• 177. Peng Y, Hu M, Lu Q et al. Flavonoids derived from Exocarpium citri Grandis inhibit LPS-induced inflammatory response via suppressing MAPK and NF-κB signalling pathways. Food Agric. Immunol. 30(1), 564–580 (2019).
  CASGoogle Scholar
• 178. Hong G-E, Kim J-A, Nagappan A et al. Flavonoids identified from Korean Scutellaria baicalensis Georgi inhibit inflammatory signaling by suppressing activation of NF-κB and MAPK in RAW 264.7 cells. Evid. Based Complement. Alternat. Med. 2013, doi: 10.1155/2013/912031 (2013) (Online).
  Google Scholar
• 179. Sen SS, Sukumaran V, Giri SS, Park SC. Flavonoid fraction of guava leaf extract attenuates lipopolysaccharide-induced inflammatory response via blocking of NF-κB signalling pathway in Exocarpium citri macrophages. Fish Shellfish Immunol. 47(1), 85–92 (2015).
  Medline CASGoogle Scholar
• 180. Nam TG, Lim T-G, Lee BH et al. Comparison of anti-inflammatory effects of flavonoid-rich common and tartary buckwheat sprout extracts in lipopolysaccharide-stimulated RAW 264.7 and peritoneal macrophages. Oxid. Med. Cell. Longev. 2017, doi: 10.1155/2017/9658030 (2017) (Online).
  MedlineGoogle Scholar
• 181. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell 169(3), 381–405 (2017).
  Medline CASGoogle Scholar
• 182. Zhang X, Jiang D, Jiang W, Zhao M, Gan J. Role of TLR4-mediated PI3K/AKT/GSK-3β signaling pathway in apoptosis of rat hepatocytes. Biomed. Res. Int. 2015, 631326 (2015).
  MedlineGoogle Scholar
• 183. Alexander W. Inhibiting the Akt pathway in cancer treatment: three leading candidates. PT 36(4), 225–227 (2011).
  MedlineGoogle Scholar
• 184. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J. Immunol. 198(3), 1006–1014 (2017).
  Medline CASGoogle Scholar
• 185. Tang F, Wang Y, Hemmings BA, Rüegg C, Xue G. PKB/Akt-dependent regulation of inflammation in cancer. Semin. Cancer Biol. 48, 62–69 (2018).
  Medline CASGoogle Scholar
• 186. Acosta-Martinez M, Cabail MZ. The PI3K/Akt pathway in meta-inflammation. Int. J. Mol. Sci. 23(23), 15330 (2022).
  Medline CASGoogle Scholar
• 187. Luo J, Manning BD, Cantley LC. Targeting the PI3K–Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4), 257–262 (2003).
  Medline CASGoogle Scholar
• 188. Jing H, Zhou X, Dong X et al. Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett. 294(2), 167–177 (2010).
  Medline CASGoogle Scholar
• 189. Song NR, Kim JE, Park JS et al. Licochalcone A, a polyphenol present in licorice, suppresses UV-induced COX-2 expression by targeting PI3K, MEK1, and B-Raf. Int. J. Mol. Sci. 16(3), 4453–4470 (2015).
  Medline CASGoogle Scholar
• 190. Lee YH, Jeon S-H, Kim SH et al. A new synthetic chalcone derivative, 2-hydroxy-3′,5,5′-trimethoxychalcone (DK-139), suppresses the toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF-κB pathway in BV2 microglial cells. Exp. Mol. Med. 44, 369–377 (2012).
  MedlineGoogle Scholar
• 191. Kim MJ, Kadayat T, Um YJ, Jeong TC, Lee ES, Park PH. Inhibitory effect of 3-(4-hydroxyphenyl)-1-(thiophen-2-yl) prop-2-en-1-one, a chalcone derivative on MCP-1 expression in macrophages via inhibition of ROS and Akt signaling. Biomol. Ther. (Seoul) 23(2), 119–127 (2015).
  Medline CASGoogle Scholar
• 192. Lee H, Cho H, Lim D, Kang Y-H, Lee K, Park J. Mechanisms by which licochalcone E exhibits potent anti-inflammatory properties: studies with phorbol ester-treated mouse skin and lipopolysaccharide-stimulated murine macrophages. Int. J. Mol. Sci. 14(6), 10926 (2013).
  MedlineGoogle Scholar
• 193. Bai D, Zhao Y, Zhu Q et al. LZ205, a newly synthesized flavonoid compound, exerts anti-inflammatory effect by inhibiting M1 macrophage polarization through regulating PI3K/AKT/mTOR signaling pathway. Exp. Cell Res. 364(1), 84–94 (2018).
  Medline CASGoogle Scholar
• 194. Park CM, Song Y-S. Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-κB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells. Nutr. Res. Pract. 7(6), 423–429 (2013).
  Medline CASGoogle Scholar
• 195. Lee H-C, Liu F-C, Tsai C-N, Chou A-H, Liao C-C, Yu H-P. Esculetin ameliorates lipopolysaccharide-induced acute lung injury in mice via modulation of the AKT/ERK/NF-κB and RORγt/IL-17 pathways. Inflammation 43(3), 962–974 (2020).
  Medline CASGoogle Scholar
• 196. Qi S, Xin Y, Guo Y et al. Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. Int. Immunopharmacol. 12(1), 278–287 (2012).
  Medline CASGoogle Scholar
• 197. Sun Y, Qin H, Zhang H et al. Fisetin inhibits inflammation and induces autophagy by mediating PI3K/AKT/mTOR signaling in LPS-induced RAW264.7 cells. Food Nutr. Res. 65, doi: 10.29219/fnr.v65.6355 (2021) (Online).
  Google Scholar
• 198. Zhao M, Li C, Shen F, Wang M, Jia N, Wang C. Naringenin ameliorates LPS-induced acute lung injury through its anti-oxidative and anti-inflammatory activity and by inhibition of the PI3K/AKT pathway. Exp. Ther. Med. 14(3), 2228–2234 (2017).
  Medline CASGoogle Scholar
• 199. Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 78(4), 1233–1261 (2021).
  Medline CASGoogle Scholar
• 200. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS–) vs. alternatively activated macrophages. Front. Immunol. 10, (2019).
  MedlineGoogle Scholar
• 201. Hirai S, Kim YI, Goto T et al. Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Sci. 81(16), 1272–1279 (2007).
  Medline CASGoogle Scholar
• 202. Wang Z, Guan Y, Yang R, Li J, Wang J, Jia A-Q. Anti-inflammatory activity of 3-cinnamoyltribuloside and its metabolomic analysis in LPS-activated RAW 264.7 cells. BMC Complement. Med. Ther. 20(1), 329 (2020).
  Google Scholar
• 203. Cao L, Li R, Chen X, Xue Y, Liu D. Neougonin A inhibits lipopolysaccharide-induced inflammatory responses via downregulation of the NF-kB signaling pathway in RAW 264.7 macrophages. Inflammation 39(6), 1939–1948 (2016).
  Medline CASGoogle Scholar
• 204. Molagoda IMN, Jayasingha JACC, Choi YH, Jayasooriya RGPT, Kang C-H, Kim G-Y. Fisetin inhibits lipopolysaccharide-induced inflammatory response by activating β-catenin, leading to a decrease in endotoxic shock. Sci. Rep. 11(1), 1–17 (2021).
  MedlineGoogle Scholar
• 205. Mendes LF, Gaspar VM, Conde TA, Mano JF, Duarte IF. Flavonoid-mediated immunomodulation of human macrophages involves key metabolites and metabolic pathways. Sci. Rep. 9(1), 1–10 (2019).
  MedlineGoogle Scholar
• 206. Yang H-L, Yang T-Y, Gowrisankar YV et al. Suppression of LPS-induced inflammation by chalcone flavokawain a through activation of Nrf2/ARE-mediated antioxidant genes and inhibition of ROS/NFκB signaling pathways in primary splenocytes. Oxid. Med. Cell. Longev. 2020, 3476212 (2020).
  Google Scholar
• 207. Park P-H, Kim HS, Hur J, Jin XY, Jin YL, Sohn DH. YL-I-108, a synthetic chalcone derivative, inhibits lipopolysaccharide-stimulated nitric oxide production in RAW 264.7 murine macrophages: involvement of heme oxygenase-1 induction and blockade of activator protein-1. Arch. Pharm. Res. 32(1), 79–89 (2009).
  Medline CASGoogle Scholar
• 208. Zhang Y, Xu T, Wu B et al. Targeting myeloid differentiation protein 2 by the new chalcone L2H21 protects LPS-induced acute lung injury. J. Cell. Mol. Med. 21(4), 746–757 (2017).
  Medline CASGoogle Scholar
• 209. Bandyopadhyay S, Romero JR, Chattopadhyay N. Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol. Cell. Endocrinol. 287(1–2), 57–64 (2008).
  Medline CASGoogle Scholar
• 210. Kim J-A, Kim D-K, Kang O-H et al. Inhibitory effect of luteolin on TNF-α-induced IL-8 production in human colon epithelial cells. Int. Immunopharmacol. 5(1), 209–217 (2005).
  Medline CASGoogle Scholar
• 211. Lee S-H, Kim Y-J, Kwon S-H et al. Inhibitory effects of flavonoids on TNF-α-induced IL-8 gene expression in HEK 293 cells. BMB Rep. 42(5), 265–270 (2009).
  Medline CASGoogle Scholar
• 212. Wilczok T. Effect of kaempferol on the production and gene expression of monocyte chemoattractant protein-1 in J774. 2 macrophages. Pharmacol. Rep. 57(107), 107–112 (2005).
  MedlineGoogle Scholar
• 213. Di Santo A, Mezzetti A, Napoleone E et al. Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J. Thromb. Haemost. 1(5), 1089–1095 (2003).
  MedlineGoogle Scholar
• 214. Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. The aromatic ketone 4′-hydroxychalcone inhibits TNFα-induced NF-κB activation via proteasome inhibition. Biochem. Pharmacol. 82(6), 620–631 (2011).
  Medline CASGoogle Scholar
• 215. Lee J-H, Jung HS, Giang PM et al. Blockade of nuclear factor-κB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J. Pharmacol. Exp. Ther. 316(1), 271–278 (2006).
  Medline CASGoogle Scholar
• 216. Furusawa J-I, Funakoshi-Tago M, Tago K et al. Licochalcone A significantly suppresses LPS signaling pathway through the inhibition of NF-κB p65 phosphorylation at serine 276. Cell. Signal. 21(5), 778–785 (2009).
  Medline CASGoogle Scholar
• 217. Xia Y, Lian S, Khoi PN et al. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells. Int. J. Oncol. 46(4), 1835–1843 (2015).
  Medline CASGoogle Scholar
• 218. Nizamutdinova IT, Kim YM, Chung JI et al. Anthocyanins from black soybean seed coats preferentially inhibit TNF-α-mediated induction of VCAM-1 over ICAM-1 through the regulation of GATAs and IRF-1. J. Agric. Food Chem. 57(16), 7324–7330 (2009).
  Medline CASGoogle Scholar
• 219. Kim MJ, Kadayat T, Kim DE, Lee ES, Park PH. TI-I-174, a synthetic chalcone derivative, suppresses nitric oxide production in murine macrophages via heme oxygenase-1 induction and inhibition of AP-1. Biomol. Ther. (Seoul) 22(5), 390 (2014).
  Medline CASGoogle Scholar
• 220. Hošek J, Toniolo A, Neuwirth O, Bolego C. Prenylated and geranylated flavonoids increase production of reactive oxygen species in mouse macrophages but inhibit the inflammatory response. J. Nat. Prod. 76(9), 1586–1591 (2013).
  Medline CASGoogle Scholar
• 221. Hämäläinen M, Nieminen R, Asmawi MZ, Vuorela P, Vapaatalo H, Moilanen E. Effects of flavonoids on prostaglandin E2 production and on COX-2 and mPGES-1 expressions in activated macrophages. Planta Med. 77(13), 1504–1511 (2011).
  Medline CASGoogle Scholar
• 222. Rullah K, Mohd Aluwi MFF, Yamin BM et al. Inhibition of prostaglandin E2 production by synthetic minor prenylated chalcones and flavonoids: synthesis, biological activity, crystal structure, and in silico evaluation. Bioorg. Med. Chem. Lett. 24(16), 3826–3834 (2014). •• Report flavonoids significantly suppress PGE2 production in mouse macrophage cells lipopolysaccharide-induced.
  Medline CASGoogle Scholar
• 223. Rullah K, Mohd Aluwi MFF, Yamin BM et al. Molecular characterization, biological activity, and in silico study of 2-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-6-methoxy-4H-chromen-4-one as a novel selective COX-2 inhibitor. J. Mol. Struct. 1081, 51–61 (2015). •• Reports flavonoids as selective COX-2 inhibitors.
  CASGoogle Scholar
• 224. Kil J-S, Son Y, Cheong Y-K et al. Okanin, a chalcone found in the genus Bidens, and 3-penten-2-one inhibit inducible nitric oxide synthase expression via heme oxygenase-1 induction in RAW264.7 macrophages activated with lipopolysaccharide. J. Clin. Biochem. Nutr. 1112130134–1112130134 (2011).
  Google Scholar
• 225. Hatziieremia S, Gray A, Ferro V, Paul A, Plevin R. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFκB signalling pathways in monocytes/macrophages. Br. J. Pharmacol. 149(2), 188–198 (2006).
  Medline CASGoogle Scholar